Januvia 100 mg 28 tablets

Tradename:

Januvia

Composition:

Each tablet contains:

Sitagliptin 100 mg

Auxiliary components:

calcium hydrogen phosphate, unmilled; croscarmellose sodium; magnesium stearate; sodium stearyl fumarate.

Properties:

Januvia@ (sitagliptin) is an orally active, highly selective inhibitor of the DPP-4 enzyme intended for the treatment of type 2 diabetes mellitus. peroxisome proliferator-activated receptors (PPAR-Y), alpha-glucosidase inhibitors, amylin analogs. By inhibiting DPP-4, sitagliptin increases the concentration of two hormones of the incretin family: GLP-I and GIP. Hormones of the incretin family are secreted in the intestine during the day, their concentration increases in response to food intake. Incretins are part of the internal physiological system of glucose homeostasis regulation.

Indications:

Monotherapy: as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes;

Combination therapy: type 2 diabetes mellitus to improve glycemic control in combination with metformin or PPAR-Y agonists (for example, thiazolidinedione), when diet and exercise in combination with the listed agents alone do not lead to adequate glycemic control.

Method of administration and dosage:

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. The compliance of the used dosage form of a particular drug with indications for use and dosage regimen should be strictly observed.

Inside. Single dose – 100 mg 1 time/day.

In case of renal failure, correction of the dosage regimen is required.

Contraindications:

Type 1 diabetes mellitus; diabetic ketoacidosis; pregnancy; lactation period (breastfeeding); children and adolescents under the age of 18; hypersensitivity to sitagliptin.

Precautions:

Use with caution in patients with renal insufficiency. In case of moderate and severe renal failure, as well as in patients with endstage renal failure who require hemodialysis, a dosage adjustment is required.

Elderly patients are more likely to develop renal failure. Accordingly, as in other age groups, dose adjustment is necessary in patients with severe renal failure.

Side effects:

• upper respiratory tract infections, nasopharyngitis
• headache
• arthralgia
• nausea, vomiting, abdominal pain, diarrhea
• acute pancreatitis, including hemorrhagic and necrotic
• an increase in uric acid in the blood, a decrease in the activity of total alkaline phosphatase and, accordingly, the bone fraction of alkaline phosphatase
• leukocytosis due to an increase in the number of neutrophils.

Storage method:

At a temperature not higher than 30 degrees.

Packaging:

The cardboard box holds 14 or 28 tablets.